



Docket No.: 160052207

TECH CENTER 160012800
SEP 18 2002
RECEIVED
[Signatures]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : M. FLASHNER-BARAK
SERIAL NO. : 09/829,621
FILING DATE : April 10, 2001
FOR : METHOD AND COMPOSITION FOR TREATING CANCER
BY ADMINISTRATION OF APOPTOSIS-INDUCING
CHEMOTHERAPEUTIC AGENTS

GROUP ART UNIT : 1615
EXAMINER : A. E. PULLIAM

ELECTION OF SPECIES AND PRELIMINARY AMENDMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed August 22, 2002, Applicant elects the polymers listed in claims 9 and 37, as amended herein. Applicant also elects paclitaxel as the chemotherapeutic. The claims readable thereon are claims 1-9, 12-18, 20-37, 40-48, 50-65. Should the Examiner find any of the generic claims to be allowable, Applicant respectfully requests that all of the species of the allowed generic claims, including those species not elected above, be examined and allowed.

Applicant also submits the following amendment to the specification and claims to correct a typographical error.

The Office is authorized to charge any underpayment or credit any overpayment associated with this application to Kenyon & Kenyon Deposit Account No. 11-0600.

In the Specification:

On page 8, paragraph 4, please substitute the following paragraph:

One embodiment of the present invention provides a plurality of microspheres made from a biodegradable polymeric matrix. The biodegradable polymer may be selected from the group consisting of polylactic acid, polyglycolic acid and a co-polymer of polyglycolic and polylactic acid.

[Signature]